Funding for this research was provided by:
health technology assessment programme (STA 13/14/25)
Accepted: 8 August 2021
First Online: 27 August 2021
: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (Grant STA 13/14/25). Please visit the HTA programme website for further project information (ExternalRef removed). This summary of the ERG report was compiled after NICE issued the FAD. This summary of the ERG report was compiled after NICE issued the FAD. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of NICE or the Department of Health. Any errors are the responsibility of the authors.
: Sabine E. Grimm, Ben Wijnen, Rob Riemsma, Debra Fayter, Nigel Armstrong, Charlotte Ahmadu, Lloyd Brandts, Kate Misso, John R. Kirwan, Jos Kleijnen and Manuela A. Joore have no conflicts of interest to declare.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
: Not applicable.
: All authors have commented on the submitted manuscript and have given their approval for the final version to be published. RR, DF, CA and JK critiqued the clinical effectiveness data reported by the company, and KM critiqued the literature searches undertaken by the company. JK provided clinical expert opinion on all aspects of this appraisal. SG, BW, NA, LB and MJ critiqued the mathematical model provided and the cost-effectiveness analyses submitted by the company. SG acts as overall guarantor for the manuscript. This summary has not been externally peer reviewed by Pharmacoeconomics.